Literature DB >> 11924717

Continuous blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats.

Yunzeng Zou1, Tsutomu Yamazaki, Keiichi Nakagawa, Haruyasu Yamada, Norio Iriguchi, Haruhiro Toko, Hiroyuki Takano, Hiroshi Akazawa, Ryozo Nagai, Issei Komuro.   

Abstract

We examined whether Ca2+ channel blockers inhibit the activation of the Ca2+-dependent phosphatase calcineurin and the development of cardiac hypertrophy in spontaneously hypertensive rats (SHR). We randomly divided 12-week-old SHR into three groups, one each receiving vehicle, bolus injection or continuous infusion of nifedipine (10 mg/kg/day) from 12 to 24 weeks of age. Systolic blood pressure (BP) and heart rate were measured every week after the treatment using the tail-cuff plethysmography method. After 4, 8 and 12 weeks of treatment, 6 rats of each group were subjected to examinations that included an assay for calcineurin activity in the heart, magnetic resonance imaging (MRI), histology and Northern blot analysis. Continuous infusion of nifedipine consistently reduced BP, whereas bolus injection resulted in a fluctuation of BP. Continuous infusion of nifedipine not only reduced left ventricular mass but also decreased the transverse diameter of cardiomyocytes, interstitial fibrosis and the expression of the atrial natriuretic peptide and brain natriuretic peptide genes in the heart, while bolus injection of nifedipine did not significantly attenuate any of these hypertrophic responses in SHR. The activity of calcineurin in the heart was strongly suppressed by continuous but not bolus infusion of nifedipine in SHR. The results indicate that continuous blockade of Ca2+ channels with nifedipine effectively suppresses the development of cardiac hypertrophy in SHR, possibly through inhibition of the calcineurin activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924717     DOI: 10.1291/hypres.25.117

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  8 in total

Review 1.  Current status of cardiac MRI in small animals.

Authors:  J-P Vallée; M K Ivancevic; D Nguyen; D R Morel; M Jaconi
Journal:  MAGMA       Date:  2004-12-16       Impact factor: 2.310

Review 2.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

3.  Distinct QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive inbred rat inter-cross.

Authors:  Bastien Llamas; Zhibin Jiang; Marie-Line Rainville; Sylvie Picard; Christian F Deschepper
Journal:  Mamm Genome       Date:  2005-10-20       Impact factor: 2.957

4.  Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy.

Authors:  Xiongwen Chen; Hiroyuki Nakayama; Xiaoying Zhang; Xiaojie Ai; David M Harris; Mingxin Tang; Hongyu Zhang; Christopher Szeto; Kathryn Stockbower; Remus M Berretta; Andrea D Eckhart; Walter J Koch; Jeffery D Molkentin; Steven R Houser
Journal:  J Mol Cell Cardiol       Date:  2010-11-25       Impact factor: 5.000

5.  Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.

Authors:  Tetsuro Ago; Yanfei Yang; Peiyong Zhai; Junichi Sadoshima
Journal:  J Cardiovasc Transl Res       Date:  2010-05-01       Impact factor: 4.132

6.  Resistance to pathologic cardiac hypertrophy and reduced expression of CaV1.2 in Trpc3-depleted mice.

Authors:  Jung Woo Han; Young Ho Lee; Su-In Yoen; Joel Abramowitz; Lutz Birnbaumer; Min Goo Lee; Joo Young Kim
Journal:  Mol Cell Biochem       Date:  2016-08-13       Impact factor: 3.396

7.  Mice lacking the Cβ subunit of PKA are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction.

Authors:  Linda C Enns; Kenneth L Bible; Mary J Emond; Warren C Ladiges
Journal:  BMC Res Notes       Date:  2010-11-16

8.  Calcium inhibitor inhibits high glucose‑induced hypertrophy of H9C2 cells.

Authors:  Xiaohong Xu; Luoyang Ruan; Xiaohua Tian; Fengjuan Pan; Cailan Yang; Guosheng Liu
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.